Johnson & Johnson plans to buy Dutch vaccine group

Sep 17, 2010

US cosmetics and pharmaceutical giant Johnson & Johnson said on Friday it intended to acquire a Dutch vaccine maker Crucell which is active in developing countries for about 1.75 billion euros.

"The companies expect that Crucell's strength in the manufacture, discovery and commercialisation of vaccines would create a strong platform for Johnson & Johnson in the market," the two firms said in a statement.

"Under the terms of the negotiations... Johnson & Johnson or an affiliate would acquire all outstanding equity of Crucell that it does not already own for approximately euro 1.75 billion (2.30 billion dollars)," it added.

Johnson & Johnson already owns 17.5 percent of Crucell.

The US firm said it would keep Crucell's headquarters in Leiden in the Netherlands and preserve jobs at the Dutch company, which employs 1,300 people.

Lasy year Crucell produced more than 115 million vaccine doses in more than 100 countries, with the most of the treatments going to developing countries.

Explore further: Acne pill benefits outweigh blood clot risk: EU agency

add to favorites email to friend print save as pdf

Related Stories

Summer time and the living is breezy

Jun 06, 2006

The U.S. hurricane season is under way and for many people in areas hit hard by 2005's hurricanes, it's going to be an uneasy summer.

Clinical trial will test new HIV/AIDS vaccine

Apr 03, 2008

A phase 1 clinical trial to test a novel HIV/AIDS vaccine has begun at Brigham and Women’s Hospital (BWH). This new vaccine aims to overcome the problem of preexisting immunity to common vaccine vectors, which is thought ...

Johnson&Johnson expands Tylenol recall

Jan 15, 2010

(AP) -- Johnson & Johnson expanded a recall of over-the-counter medications Friday, the second time it has done so in less than a month because of a moldy smell that has made users sick.

Farmers relying on roundup lose some of its benefit

Apr 14, 2009

(PhysOrg.com) -- Roundup Ready crops have made weed control much easier for farmers, but a new study shows their reliance on the technology may be weakening the herbicide's ability to control weeds.

Recommended for you

First influenza vaccine brought to clinical testing

May 17, 2013

Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...

Aspirin not always best treatment for many individuals

May 16, 2013

(Medical Xpress)—An aspirin a day may not always keep heart disease away, say two University of Florida cardiologists. But a new algorithm they have developed outlines factors physicians should weigh as ...

FDA: lower ambien's dose to prevent drowsy driving

May 15, 2013

(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard ...

Simponi approved for ulcerative colitis

May 15, 2013

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

FDA approves genetic test for lung cancer drug

May 14, 2013

The Food and Drug Administration says it approved a genetic test from Roche to help doctors identify patients who can benefit from a lung cancer drug made by Genentech.

User comments : 0

More news stories

Heat-related deaths in Manhattan projected to rise

Residents of Manhattan will not just sweat harder from rising temperatures in the future, says a new study; many may die. Researchers say deaths linked to warming climate may rise some 20 percent by the 2020s, ...

Kinks and curves at the nanoscale

One of the basic principles of nanotechnology is that when you make things extremely small—one nanometer is about five atoms wide, 100,000 times smaller than the diameter of a human hair—they are going ...